Single-Domain Antibody-Based Autophagosome-Targeting Chimera for Tau Clearance and Motor Function Restoration in Tauopathies
Sigurdsson, E.; Jiang, Y.; Tetlow, A. M.; Lin, Y.; Ji, C.; Laborc, K. F.; Mar, A. C.; Pan, R.; Kong, X.-P.; Congdon, E. E.
Show abstract
Tauopathies are neurodegenerative diseases characterized by pathological tau accumulation, leading to motor and neuropsychiatric symptoms. Effective tau-targeting therapies remain a major challenge. Here, we present 1D9-LIR{Delta}TP53INP2, a single-domain antibody (sdAb)-based protein degrader that facilitates tau clearance via the autophagy-lysosomal pathway. This engineered molecule combines the anti-tau sdAb 1D9 with an LC3-interacting region (LIR{Delta}TP53INP2) to promote autophagosomal recruitment, mimicking autophagy receptors by simultaneously binding tau and LC3. In frontotemporal dementia (FTD) patient-derived neurons and JNPL3 tauopathy mice, both harboring the P301L tau mutation, 1D9-LIR{Delta}TP53INP2 significantly reduced tau levels and improved motor function in mice. These findings underscore the therapeutic potential of sdAb-based protein degraders for tauopathies. Given the challenges of brain delivery for conventional antibodies, sdAbs with enhanced brain penetration and efficacy offer a promising strategy for treatment of neurodegenerative diseases.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- β-Amyloid Induces Microglial Expression of GPC4 and APOE Leading to Increased Neuronal Tau Pathology and Toxicity 96%
- SETD7-mediated lysine monomethylation is abundant on non-hyperphosphorylated nuclear Tau 95%
- Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies 95%
Similar papers in this journal
- Tau phosphorylated at serine 356 is associated with Alzheimer's disease pathology and can be lowered in mouse and human brain tissue using the NUAK inhibitor WZ4003 97%
- Tau seeding and spreading in vivo is supported by both AD-derived fibrillar and oligomeric tau 96%
- Genome-wide association study and functional validation implicates JADE1 in tauopathy 96%
Similar papers in this journal
- A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies 97%
- MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity 96%
- Glycation of alpha-synuclein enhances aggregation and neuroinflammatory responses 96%
Similar papers in this journal
- Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment 96%
- APOE2 gene therapy reduces amyloid deposition, and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease 95%
- RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.